These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 36609487)

  • 21. The disruption of the CCDC6 - PP4 axis induces a BRCAness like phenotype and sensitivity to PARP inhibitors in high-grade serous ovarian carcinoma.
    Morra F; Merolla F; Damia G; Ricci F; Varricchio S; Ilardi G; Arenare L; Califano D; Napolitano V; Fruscio R; Melillo RM; Palazzo L; Celetti A
    J Exp Clin Cancer Res; 2022 Aug; 41(1):245. PubMed ID: 35964058
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combining EHMT and PARP Inhibition: A Strategy to Diminish Therapy-Resistant Ovarian Cancer Tumor Growth while Stimulating Immune Activation.
    Nguyen LL; Watson ZL; Ortega R; Woodruff ER; Jordan KR; Iwanaga R; Yamamoto TM; Bailey CA; To F; Jeong AD; Guntupalli SR; Behbakht K; Gibaja V; Arnoult N; Cocozaki A; Chuong EB; Bitler BG
    Mol Cancer Ther; 2024 Jun; ():OF1-OF16. PubMed ID: 38863225
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting PARP-1 with metronomic therapy modulates MDSC suppressive function and enhances anti-PD-1 immunotherapy in colon cancer.
    Ghonim MA; Ibba SV; Tarhuni AF; Errami Y; Luu HH; Dean MJ; El-Bahrawy AH; Wyczechowska D; Benslimane IA; Del Valle L; Al-Khami AA; Ochoa AC; Boulares AH
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33495297
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Heterogeneity and Clonal Evolution of Acquired PARP Inhibitor Resistance in
    Färkkilä A; Rodríguez A; Oikkonen J; Gulhan DC; Nguyen H; Domínguez J; Ramos S; Mills CE; Pérez-Villatoro F; Lazaro JB; Zhou J; Clairmont CS; Moreau LA; Park PJ; Sorger PK; Hautaniemi S; Frias S; D'Andrea AD
    Cancer Res; 2021 May; 81(10):2774-2787. PubMed ID: 33514515
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combining EHMT and PARP Inhibition: A Strategy to Diminish Therapy-Resistant Ovarian Cancer Tumor Growth while Stimulating Immune Activation.
    Nguyen LL; Watson ZL; Ortega R; Woodruff ER; Jordan KR; Iwanaga R; Yamamoto TM; Bailey CA; To F; Jeong AD; Guntupalli SR; Behbakht K; Gibaja V; Arnoult N; Cocozaki A; Chuong EB; Bitler BG
    Mol Cancer Ther; 2024 May; ():. PubMed ID: 38714351
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Poly(adenosine diphosphate ribose) polymerase inhibitors induce autophagy-mediated drug resistance in ovarian cancer cells, xenografts, and patient-derived xenograft models.
    Santiago-O'Farrill JM; Weroha SJ; Hou X; Oberg AL; Heinzen EP; Maurer MJ; Pang L; Rask P; Amaravadi RK; Becker SE; Romero I; Rubio MJ; Matias-Guiu X; Santacana M; Llombart-Cussac A; Poveda A; Lu Z; Bast RC
    Cancer; 2020 Feb; 126(4):894-907. PubMed ID: 31714594
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of the triazene compound CT913 on ovarian cancer cells in vitro and its synergistic interaction with the PARP-inhibitor olaparib.
    Wichmann C; Klotz DM; Zeiler HJ; Hilger RA; Grützmann K; Krüger A; Aust D; Wimberger P; Kuhlmann JD
    Gynecol Oncol; 2020 Dec; 159(3):850-859. PubMed ID: 32980128
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer.
    Ding L; Kim HJ; Wang Q; Kearns M; Jiang T; Ohlson CE; Li BB; Xie S; Liu JF; Stover EH; Howitt BE; Bronson RT; Lazo S; Roberts TM; Freeman GJ; Konstantinopoulos PA; Matulonis UA; Zhao JJ
    Cell Rep; 2018 Dec; 25(11):2972-2980.e5. PubMed ID: 30540933
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting GPX4-mediated ferroptosis protection sensitizes BRCA1-deficient cancer cells to PARP inhibitors.
    Xie X; Chen C; Wang C; Guo Y; Sun B; Tian J; Yan J; Li D; Chen G
    Redox Biol; 2024 Oct; 76():103350. PubMed ID: 39265497
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PARP inhibition synergizes with CD47 blockade to promote phagocytosis by tumor-associated macrophages in homologous recombination-proficient tumors.
    Liu Y; Xue R; Duan X; Shang X; Wang M; Wang F; Zhu L; Zhang L; Ge X; Zhao X; Guo H; Wang Z; Zhang L; Gao X; Shen A; Sheng Y; Qin Z
    Life Sci; 2023 Aug; 326():121790. PubMed ID: 37211345
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) Trial in Acquired PARP Inhibitor-Resistant Homologous Recombination-Deficient Ovarian Cancer.
    Wethington SL; Shah PD; Martin L; Tanyi JL; Latif N; Morgan M; Torigian DA; Rodriguez D; Smith SA; Dean E; Domchek SM; Drapkin R; Shih IM; Brown EJ; Hwang WT; Armstrong DK; Gaillard S; Giuntoli R; Simpkins F
    Clin Cancer Res; 2023 Aug; 29(15):2800-2807. PubMed ID: 37097611
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance.
    Nesic K; Krais JJ; Wang Y; Vandenberg CJ; Patel P; Cai KQ; Kwan T; Lieschke E; Ho GY; Barker HE; Bedo J; Casadei S; Farrell A; Radke M; Shield-Artin K; Penington JS; Geissler F; Kyran E; Betsch R; Xu L; Zhang F; Dobrovic A; Olesen I; Kristeleit R; Oza A; McNeish I; Ratnayake G; Traficante N; ; DeFazio A; Bowtell DDL; Harding TC; Lin K; Swisher EM; Kondrashova O; Scott CL; Johnson N; Wakefield MJ
    Mol Cancer; 2024 Aug; 23(1):158. PubMed ID: 39103848
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors.
    Lu X; He Y; Johnston RL; Nanayakarra D; Sankarasubramanian S; Lopez JA; Friedlander M; Kalimutho M; Hooper JD; Raninga PV; Khanna KK
    J Exp Clin Cancer Res; 2022 Dec; 41(1):355. PubMed ID: 36539830
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BRCA1-Mediated Dual Regulation of Ferroptosis Exposes a Vulnerability to GPX4 and PARP Co-Inhibition in BRCA1-Deficient Cancers.
    Lei G; Mao C; Horbath AD; Yan Y; Cai S; Yao J; Jiang Y; Sun M; Liu X; Cheng J; Xu Z; Lee H; Li Q; Lu Z; Zhuang L; Chen MK; Alapati A; Yap TA; Hung MC; You MJ; Piwnica-Worms H; Gan B
    Cancer Discov; 2024 Aug; 14(8):1476-1495. PubMed ID: 38552003
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic.
    Cerrato A; Morra F; Celetti A
    J Exp Clin Cancer Res; 2016 Nov; 35(1):179. PubMed ID: 27884198
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality-An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness.
    Gralewska P; Gajek A; Marczak A; Mikuła M; Ostrowski J; Śliwińska A; Rogalska A
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352723
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sequential Targeting of PLK1 and PARP1 Reverses the Resistance to PARP Inhibitors and Enhances Platin-Based Chemotherapy in BRCA-Deficient High-Grade Serous Ovarian Cancer with KRAS Amplification.
    Gasimli K; Raab M; Tahmasbi Rad M; Kurunci-Csacsko E; Becker S; Strebhardt K; Sanhaji M
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142803
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genomic and expressional dynamics of ovarian cancer cell lines in PARPi treatment revealed mechanisms of acquired resistance.
    Cheng A; Rao Q; Liu Y; Huang C; Li J; Huo C; Lin Z; Lu H
    Gynecol Oncol; 2022 Dec; 167(3):502-512. PubMed ID: 36270832
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HMGB3 promotes PARP inhibitor resistance through interacting with PARP1 in ovarian cancer.
    Ma H; Qi G; Han F; Lu W; Peng J; Li R; Yan S; Yuan C; Kong B
    Cell Death Dis; 2022 Mar; 13(3):263. PubMed ID: 35332131
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Olaparib-Resistant
    Biegała Ł; Gajek A; Marczak A; Rogalska A
    Cells; 2023 Mar; 12(7):. PubMed ID: 37048111
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.